Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients
Muneerah M Aleissa(Brigham and Women's Hospital), Amy C Sherman(Dana-Farber Cancer Institute), Guohai Zhou(Brigham and Women's Hospital), Isabel H Gonzalez-Bocco(Brigham and Women's Hospital), Sarah P. Hammond(Dana-Farber Cancer Institute), Caron A. Jacobson(Dana-Farber Cancer Institute), Sonya Davey(Brigham and Women's Hospital), Anna Saucier(Dana-Farber Cancer Institute), Jessica S Little(Brigham and Women's Hospital), Jennifer L. Crombie(Dana-Farber Cancer Institute), Nicolas C. Issa(Dana-Farber Cancer Institute), Lindsey R. Baden(Brigham and Women's Hospital), Andrew Looka(Dana-Farber Cancer Institute)
Cited by 15
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981
Influence of Human Immunodeficiency Virus Infection on the Course of Hepatitis C Virus Infection: A Meta‐Analysis
|Clinical Infectious Diseases|2001|969